Xianghui Du

652 total citations
27 papers, 353 citations indexed

About

Xianghui Du is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Xianghui Du has authored 27 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 8 papers in Surgery. Recurrent topics in Xianghui Du's work include Lung Cancer Diagnosis and Treatment (9 papers), Esophageal Cancer Research and Treatment (8 papers) and Gastric Cancer Management and Outcomes (6 papers). Xianghui Du is often cited by papers focused on Lung Cancer Diagnosis and Treatment (9 papers), Esophageal Cancer Research and Treatment (8 papers) and Gastric Cancer Management and Outcomes (6 papers). Xianghui Du collaborates with scholars based in China. Xianghui Du's co-authors include Liming Sheng, Yongling Ji, Guoqin Qiu, Xia Zhou, Dan Su, Danhong Zhang, Jianxiang Chen, Yang Yang, Xiaojiang Sun and Hao Jiang and has published in prestigious journals such as Journal of Clinical Oncology, Oncotarget and BMC Cancer.

In The Last Decade

Xianghui Du

26 papers receiving 350 citations

Peers

Xianghui Du

PRM

ONCOL

SURGE

Yongling Ji China

Guoqin Qiu China

Xiangyang Yu China

Angelika Terbuch Austria

Yiming Zhao China

Pauline du Rusquec France

Sarah Caulfield United States

Butuo Li China

Johanna Jesche Austria

Yongling Ji China

Xianghui Du

130 ×0.8

PRM

161 ×1.0

ONCOL

93 ×0.9

SURGE

63 ×0.7

68 ×0.8

Citations per year, relative to Xianghui Du Xianghui Du (= 1×) peers Yongling Ji

Countries citing papers authored by Xianghui Du

Since Specialization

Citations

This map shows the geographic impact of Xianghui Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xianghui Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xianghui Du more than expected).

Fields of papers citing papers by Xianghui Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xianghui Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xianghui Du. The network helps show where Xianghui Du may publish in the future.

Co-authorship network of co-authors of Xianghui Du

This figure shows the co-authorship network connecting the top 25 collaborators of Xianghui Du. A scholar is included among the top collaborators of Xianghui Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xianghui Du. Xianghui Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Yi‐Long, Qing Zhou, Yi Pan, et al.. (2024). Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 8082–8082. 1 indexed citations

Qiu, Guoqin, et al.. (2023). Circ_0001955 promotes non‐small cell lung cancer cell proliferation and invasion by regulating MiR‐29a‐3p/NKIRAS2 axis to activate the nuclear factor‐κB pathway. Pathology International. 73(9). 434–443.

Fang, Min, et al.. (2023). Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world. Clinical & Experimental Metastasis. 40(5). 423–429. 6 indexed citations

Sheng, Liming, Jing Yang, Danhong Zhang, et al.. (2023). Radiation pneumonia predictive model for radiotherapy in esophageal carcinoma patients. BMC Cancer. 23(1). 988–988. 7 indexed citations

Chen, Ying, Xiaoying Cui, Di Wang, et al.. (2022). Molecular Characterization and Prognostication of Large Cell Neuroendocrine Carcinoma and Large Cell Carcinoma. Frontiers in Oncology. 11. 664397–664397. 8 indexed citations

Zeng, Jing, et al.. (2021). Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma. Cancer/Radiothérapie. 25(5). 441–446. 3 indexed citations

Yang, Yang, Yu Chong, Mengyuan Chen, et al.. (2021). Targeting lactate dehydrogenase a improves radiotherapy efficacy in non-small cell lung cancer: from bedside to bench. Journal of Translational Medicine. 19(1). 170–170. 51 indexed citations

Yang, Yang, Xiaofang Xu, Xia Zhou, et al.. (2020). Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy. Frontiers in Oncology. 10. 1431–1431. 13 indexed citations

Sheng, Liming, et al.. (2019). High incidence of radiation pneumonitis in lung cancer patients with chronic silicosis treated with radiotherapy. Journal of Radiation Research. 61(1). 117–122. 7 indexed citations

10.

Chen, Guofu, Liming Sheng, & Xianghui Du. (2018). Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma. Cancer Chemotherapy and Pharmacology. 82(3). 505–510. 14 indexed citations

11.

Chen, Ying, et al.. (2018). Network analysis of differentially expressed smoking‑associated mRNAs, lncRNAs and miRNAs reveals key regulators in smoking‑associated lung cancer. Experimental and Therapeutic Medicine. 16(6). 4991–5002. 17 indexed citations

12.

Ji, Yongling, et al.. (2016). A phase I dose escalation study of S-1 with concurrent radiotherapy in elderly patients with esophageal cancer. Journal of Thoracic Disease. 8(3). 451–458. 11 indexed citations

13.

Qiu, Guoqin, Xianghui Du, Liming Sheng, et al.. (2016). Differences in displacement of the proximal and distal ends of mid-upper thoracic esophageal squamous cell carcinoma. Molecular and Clinical Oncology. 5(1). 143–147. 1 indexed citations

14.

Qiu, Guoqin, Xianghui Du, Xia Zhou, et al.. (2016). Prophylactic cranial irradiation in 399 patients with limited-stage small cell lung cancer. Oncology Letters. 11(4). 2654–2660. 11 indexed citations

15.

Wang, Shengye, Xianghui Du, Xue Bai, et al.. (2015). Use of maximum heart distance to evaluate heart dosimetry for tangential field radiotherapy in left-sided breast cancer after modified radical mastectomy. Zhonghua fangshe zhongliuxue zazhi. 24(2). 180–183. 1 indexed citations

16.

Du, Xianghui, Liming Sheng, & Yongling Ji. (2015). Perineural invasion correlates with postoperative distant metastasis and poor overall survival in patients with PT1–3N0M0 esophageal squamous cell carcinoma. OncoTargets and Therapy. 8. 3153–3153. 9 indexed citations

17.

Ji, Yongling, Liming Sheng, Xianghui Du, Guoqin Qiu, & Dan Su. (2014). Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients. Platelets. 26(2). 138–142. 44 indexed citations

18.

Ji, Yongling, Liming Sheng, Xianghui Du, et al.. (2014). Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.. PubMed. 6(7). 896–904. 9 indexed citations

19.

Xu, Yaping, Jinshi Liu, Xianghui Du, et al.. (2013). Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. Radiation Oncology. 8(1). 116–116. 40 indexed citations

20.

Xu, Yaping, Shenglin Ma, Yongling Ji, et al.. (2010). Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study. Lung Cancer. 72(3). 327–332. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact